NCT01332968 2022-08-11A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)Hoffmann-La RochePhase 3 Completed1,401 enrolled 40 charts
NCT01059630 2020-01-13A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)Genentech, Inc.Phase 3 Completed413 enrolled 34 charts